MedPage Today

Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic Responses

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...
The Globe and Mail

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...
ascopubs.org

Reply to: “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?”

Reply to “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?” The following represents disclosure ...
Yahoo Finance

Personalis Announces New Data from a Landmark Neoadjuvant Lung Cancer Trial Showing Superiority of Ultra-Sensitive, Tumor-Informed MRD Testing

FREMONT, Calif., September 03, 2025--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical ...